Ny!
Biosimilar Clinical Development: Scientific Considerations and New Methodologies
Kerry B. Barker (Redaktør) Sandeep M. Menon (Redaktør) Ralph B. D'Agostino, Sr. (Redaktør) Siyan Xu (Redaktør) Bo Jin, PhD (Redaktør)
«
"Thus, the book Biosimilar Clinical Development contains five chapters discussing general issues involving biosimilars. The remaining six chapters present statistical methods, many of which are new, and their applications in bioequivalence and biosimilarity studies; they are really research papers. . . It will appeal to readers interested in biosimilars and especially in their statistical assessments."
~Laszlo Endrenyi, University of Toronto“The book is edited by a team of renowned experts from both statistics and biosimilar clinical development. It contains 11 chapters, covering not only statistical issues but also pre-clinical and clinical development issues not regularly discussed on this kind of book, as well as references to regulatory considerations of upmost importance for statisticians working in the strongly regulated environment of clinical development . . . I strongly recommend the reading of this book. In my opinion, the book should be a must-have reading for professionals who work regularly with biosimilars and want to have an overview of state-of-the art methods for 'hot-topics' in the analysis and planning of clinical trials for this purpose.”
»
~David Manteigas
Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Les mer
Logg inn for å se din bonus
Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.
Detaljer
- Forlag
- Chapman & Hall/CRC
- Innbinding
- Paperback
- Språk
- Engelsk
- Sider
- 248
- ISBN
- 9780367736521
- Utgivelsesår
- 2020
- Format
- 23 x 16 cm
Anmeldelser
«
"Thus, the book Biosimilar Clinical Development contains five chapters discussing general issues involving biosimilars. The remaining six chapters present statistical methods, many of which are new, and their applications in bioequivalence and biosimilarity studies; they are really research papers. . . It will appeal to readers interested in biosimilars and especially in their statistical assessments."
~Laszlo Endrenyi, University of Toronto“The book is edited by a team of renowned experts from both statistics and biosimilar clinical development. It contains 11 chapters, covering not only statistical issues but also pre-clinical and clinical development issues not regularly discussed on this kind of book, as well as references to regulatory considerations of upmost importance for statisticians working in the strongly regulated environment of clinical development . . . I strongly recommend the reading of this book. In my opinion, the book should be a must-have reading for professionals who work regularly with biosimilars and want to have an overview of state-of-the art methods for 'hot-topics' in the analysis and planning of clinical trials for this purpose.”
»
~David Manteigas
«
"Thus, the book Biosimilar Clinical Development contains five chapters discussing general issues involving biosimilars. The remaining six chapters present statistical methods, many of which are new, and their applications in bioequivalence and biosimilarity studies; they are really research papers. . . It will appeal to readers interested in biosimilars and especially in their statistical assessments."
~Laszlo Endrenyi, University of Toronto“The book is edited by a team of renowned experts from both statistics and biosimilar clinical development. It contains 11 chapters, covering not only statistical issues but also pre-clinical and clinical development issues not regularly discussed on this kind of book, as well as references to regulatory considerations of upmost importance for statisticians working in the strongly regulated environment of clinical development . . . I strongly recommend the reading of this book. In my opinion, the book should be a must-have reading for professionals who work regularly with biosimilars and want to have an overview of state-of-the art methods for 'hot-topics' in the analysis and planning of clinical trials for this purpose.”
»
~David Manteigas
Medlemmers vurdering
Skriv en vurdering
Oppdag mer
Bøker som ligner på Biosimilar Clinical Development: Scientific Considerations and New Methodologies:
Ny!